![[Latest] Global Neonatal Intensive Care Respiratory Devices Market Size/Share Worth USD 5.7 Billion by 2035 at a 10.5% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, SWOT Analysis)](https://s.yimg.com/uu/api/res/1.2/JDc8Q43tjkZAOscxTVa7kA--~B/Zmk9c3RyaW07aD02Mzt3PTg0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/0bec09301614ea6a3ee415db83086891.cf.webp)
NYSE - Nasdaq Real Time Price USD
ResMed Inc. (RMD)
196.50 +5.24 (+2.74%)
At close: 4:00:03 PM EDT
195.00 -1.50 (-0.76%)
After hours: 4:25:32 PM EDT
Trade ResMed on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreChart Range Bar
Loading chart for RMD
- Previous Close
191.26 - Open
193.43 - Bid 196.32 x 10000
- Ask 195.42 x 10000
- Day's Range
192.35 - 197.60 - 52 Week Range
180.27 - 293.81 - Volume
1,123,044 - Avg. Volume
1,378,485 - Market Cap (intraday)
28.504B - Beta (5Y Monthly) 0.78
- PE Ratio (TTM)
18.95 - EPS (TTM)
10.37 - Earnings Date Apr 30, 2026
- Forward Dividend & Yield 2.40 (1.25%)
- Ex-Dividend Date May 14, 2026
- 1y Target Est
260.60
Recent News
View More
Performance Overview
Trailing total returns as of 6/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
RMD
17.99%
S&P 500 (^GSPC)
7.49%
1-Year Return
RMD
22.46%
S&P 500 (^GSPC)
20.78%
3-Year Return
RMD
6.01%
S&P 500 (^GSPC)
69.22%
5-Year Return
RMD
16.51%
S&P 500 (^GSPC)
72.47%
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
As of 6/23/2026
Market Cap
27.74B
Enterprise Value
26.93B
Trailing P/E
18.44
Forward P/E
16.13
PEG Ratio (5yr expected)
1.12
Price/Sales (ttm)
5.06
Price/Book (mrq)
4.27
Enterprise Value/Revenue
4.86
Enterprise Value/EBITDA
12.35
Financial Highlights
Profitability and Income Statement
Profit Margin
27.44%
Return on Assets (ttm)
14.71%
Return on Equity (ttm)
25.25%
Revenue (ttm)
5.54B
Net Income Avi to Common (ttm)
1.52B
Diluted EPS (ttm)
10.37
Balance Sheet and Cash Flow
Total Cash (mrq)
1.66B
Total Debt/Equity (mrq)
12.99%
Levered Free Cash Flow (ttm)
1.45B
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Mkt Cap undefined -
Industry -
340.41
+1.20%
Mkt Cap 24.049B
Industry Medical Instruments & Supplies
147.77
+2.68%
Mkt Cap 40.717B
Industry Medical Instruments & Supplies
401.83
-0.33%
Mkt Cap 142.313B
Industry Medical Instruments & Supplies
Company Insights
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected. Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports
View MoreLowering target price to $213.00
RESMED INC has an Investment Rating of BUY; a target price of $213.000000; an Industry Subrating of Medium; a Management Subrating of High; a Safety Subrating of High; a Financial Strength Subrating of High; a Growth Subrating of High; and a Value Subrating of Medium.
RatingPrice TargetRaising target price to $217.00
RESMED INC has an Investment Rating of BUY; a target price of $217.000000; an Industry Subrating of Medium; a Management Subrating of High; a Safety Subrating of High; a Financial Strength Subrating of High; a Growth Subrating of High; and a Value Subrating of Medium.
RatingPrice TargetLowering target price to $201.00
RESMED INC has an Investment Rating of BUY; a target price of $201.000000; an Industry Subrating of High; a Management Subrating of High; a Safety Subrating of High; a Financial Strength Subrating of High; a Growth Subrating of High; and a Value Subrating of Medium.
RatingPrice TargetResMed: Shares Undervalued on Solid Demand Profile
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
RatingPrice Target